Sentinel node and bone marrow micrometastases and nanometastases

Current Breast Cancer Reports

Volumn 2, Issue 2, 2010, Pages 96-106

  Biganzoli, Elia ^a   Pedriali, Massimo ^b   Querzoli, Patrizia ^b   Nenci, Italo ^b   Iacobelli, Stefano ^c   Piantelli, Mauro ^c   Alberti, Saverio ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Bone marrow; Breast cancer; Lymph nodes; Markers; Metastasis; Prognosis

Indexed keywords

BONE MARROW METASTASIS; BREAST CANCER; CANCER CLASSIFICATION; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; EVENT FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MICROMETASTASIS; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY ANALYSIS; SENTINEL LYMPH NODE; STATISTICAL ANALYSIS;

EID: 77953139655     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-010-0013-5     Document Type: Review

References (65)

1. De Vita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology, 8th Edition. Edited by De Vita VT, Lawrence TS, Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins; 2008:1595-1654.
2. Cummings MC, Walsh MD, Hohn BG, et al.: Occult axillary lymph node metastases in breast cancer do matter: results of 10-year survival analysis. Am J Surg Pathol 2002, 26:1286-1295.
3. Clare SE, Sener SF, Wilkens W, et al.: Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann Surg Oncol 1997, 4:447-451.
4. Querzoli P, Pedriali M, Rinaldi R, et al.: Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin Cancer Res 2006, 12:6696-6701.
5. Cote RJ, Peterson HF, Chaiwun B, et al.: Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999, 354:896-900.
6. Lara JF, Young SM, Velilla RE, et al.: The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 2003, 98:2105-2113.
7. Nasser IA, Lee AK, Bosari S, et al.: Occult axillary lymph node metastases in "node-negative" breast carcinoma. Hum Pathol 1993, 24:950-957.
8. Trojani M, de Mascarel I, Bonichon F, et al.: Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987, 55:303-306. (Pubitemid 17036845)
9. Singletary SE, Allred C, Ashley P, et al.: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002, 20:3628-3636.
10. Braun S, Kentenich C, Janni W, et al.: Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer Patients. J Clin Oncol 2000, 18:80.
11. McGuckin MA, Cummings MC, Walsh MD, et al.: Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer 1996, 73:88-95.
12. de Mascarel I, MacGrogan G, Picot V, et al.: Prognostic significance of immunohistochemically detected breast cancer node metastases in 218 patients. Br J Cancer 2002, 87:70-74.
13. Dabbs DJ, Fung M, Landsittel D, et al.: Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J 2004, 10:101-105.
14. Reed W, Bohler PJ, Sandstad B, et al.: Occult metastases in axillary lymph nodes as a predictor of survival in node-negative breast carcinoma with long-term follow-up. Breast J 2004, 10:174-180.
15. Chagpar A, Middleton LP, Sahin AA, et al.: Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer 2005, 103:1581-1586.
16. Colleoni M, Rotmensz N, Peruzzotti G, et al.: Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol 2005, 23:1379-1389.
17. Tan LK, Giri D, Hummer AJ, et al.: Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol 2008, 26:1803-1809. This is a detailed subgroup analysis of the impact of micrometastases and nanometastases according to cell number, maximum diameter, lymph node anatomical location, and conventional prognostic markers.
18. Truong PT, Vinh-Hung V, Cserni G, et al.: The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer. Eur J Cancer 2008, 44:1670-1677.
19. Hansen NM, Grube B, Ye X, et al.: Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol 2009, 27:4679-4684.
20. Montagna E, Viale G, Rotmensz N, et al.: Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breast Cancer Res Treat 2009, 118:385-394.
21. Park D, Karesen R, Naume B, et al.: The prognostic impact of occult nodal metastasis in early breast carcinoma. Breast Cancer Res Treat 2009, 118:57-66.
22. Reed J, Rosman M, Verbanac KM, et al.: Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg 2009, 208:333-340.
23. Masci G, Di Tommaso L, Del Prato I, et al.: Sinusal localization of nodal micrometastases is a prognostic factor in breast cancer. Ann Oncol 2009 (in press).
24. Steinhoff MM: Axillary node micrometastases: detection and biologic significance. Breast J 1999, 5:325-329.
25. de Boer M, van Deurzen CH, van Dijck JA, et al.: Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009, 361:653-663. This is a major study showing an impact of micrometastases and nanometastases on prognosis and on response to therapy.
26. Langer I, Guller U, Viehl CT, et al.: Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol 2009, 16:3366-3374.
27. Bulte CS, van der Heiden-van der Loo M, Hennipman A: Axillary recurrence rate after tumour negative and micrometastatic positive sentinel node procedures in breast cancer patients, a population based multicenter study. Eur J Surg Oncol 2009, 35:25-31.
28. Cserni G: A model for determining the optimum histology of sentinel lymph nodes in breast cancer. J Clin Pathol 2004, 57:467-471.
29. Kiricuta CI, Tausch J: A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992, 69: 2496-2501.
30. Weaver DL, Krag DN, Ashikaga T, et al.: Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 2000, 88:1099-1107.
31. van Deurzen CH, de Boer M, Monninkhof EM, et al.: Nonsentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node. J Natl Cancer Inst 2008, 100:1574-1580.
32. Veronesi U, Paganelli G, Viale G, et al.: Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006, 7:983-990.
33. Blumencranz P, Whitworth PW, Deck K, et al.: Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am J Surg 2007, 194:426-432.
34. Cserni G, Gregori D, Merletti F, et al.: Meta-analysis of nonsentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004, 91:1245-1252.
35. Pantel K, Brakenhoff RH, Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008, 8:329-340. This is a recent review on the impact of BM microinvasion on the biological history of breast cancer, on the molecular mechanisms underlying diffusion, and on current detection methods.
36. Braun S, Pantel K, Muller P, et al.: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000, 342:525-533.
37. Wiedswang G, Borgen E, Karesen R, et al.: Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003, 21:3469-3478.
38. Braun S, Vogl FD, Naume B, et al.: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353:793-802. (Pubitemid 41215488)
39. Naume B, Zhao X, Synnestvedt M, et al.: Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol 2007, 1:160-171.
40. Schwarzenbach H, Pantel K, Kemper B, et al.: Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res 2009, 11:R71.
41. Husemann Y, Geigl JB, Schubert F, et al.: Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68.
42. Bartkowiak K, Wieczorek M, Buck F, et al.: Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/ progenitor cell protein profile. J Proteome Res 2009, 8:2004-2014.
43. Bankhead C: Debate over sentinel node biopsy continues. J Natl Cancer Inst 2007, 99:751-753.
44. Demicheli R, Retsky MW, Hrushesky WJ, et al.: Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 2007, 4:699-710.
45. Gangnus R, Langer S, Breit E, et al.: Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res 2004, 10:3457-3464.
46. Gray JW: Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell 2003, 4:4-6.
47. Demicheli R, Terenziani M, Valagussa P, et al.: Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst 1994, 86:45-48.
48. Demicheli R, Valagussa P, Bonadonna G: Double-peaked time distribution of mortality for breast cancer patients undergoing mastectomy. Breast Cancer Res Treat 2002, 75:127-134.
49. van der Ploeg IM, Nieweg OE, van Rijk MC, et al.: Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature. Eur J Surg Oncol 2008, 34:1277-1284.
50. Rutgers E: Micrometastases in the sentinel node: take it or leave it? Presented at San Antonio Breast Cancer Symposium. San Antonio, TX; December 14-17, 2006.
51. Zavagno G, Del Bianco P, Koussis H, et al.: Clinical impact of false-negative sentinel lymph nodes in breast cancer. Eur J Surg Oncol 2008, 34:620-625.
52. Veronesi U, Paganelli G, Viale G, et al.: Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999, 91:368-373.
53. Viale G, Dell'Orto P, Biasi MO, et al.: Comparative evaluation of an extensive histopathologic examination and a real-time reversetranscription- polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients. Ann Surg 2008, 247:136-142.
54. Julian TB, Blumencranz P, Deck K, et al.: Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol 2008, 26:3338-3345.
55. Veys I, Majjaj S, Salgado R, et al.: Evaluation of the histological size of the sentinel lymph node metastases using RT-PCR assay: a rapid tool to estimate the risk of non-sentinel lymph node invasion in patients with breast cancer. Breast Cancer Res Treat 2009 (in press).
56. Blumencranz R: Multiplex molecular assay has improved sensitivity over histological intra-operative nodal metastases tests for breast cancer patients-results from a large multi-center trial. Presented at San Antonio Breast Cancer Symposium. San Antonio, TX; December 14-17, 2006.
57. Kahn HJ, Hanna WM, Chapman JA, et al.: Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J 2006, 12:294-301.
58. de Mascarel I, Bonichon F, Coindre JM, et al.: Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992, 66:523-527.
59. Hainsworth PJ, Tjandra JJ, Stillwell RG, et al.: Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993, 80:459-463.
60. Sedmak DD, Meineke TA, Knechtges DS, et al.: Prognostic significance of cytokeratin-positive breast cancer metastases. Mod Pathol 1989, 2:516-520.
61. Riethdorf S, Fritsche H, Muller V, et al.: Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007, 13:920-928. (Pubitemid 46340368)
62. Cristofanilli M, Hayes DF, Budd GT, et al.: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23:1420-1430.
63. Fehm T, Hoffmann O, Aktas B, et al.: Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009, 11:R59.
64. Braun S, Cevatli BS, Assemi C, et al.: Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J. Clin Oncol 2001, 19:1468-1475.
65. Biganzoli E, Boracchi P, Daidone MG, et al.: Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers. Int J Biol Markers 1998, 13:107-123.